April 24, 2017
Potassium phosphates injection from Fresenius Kabi USA, LLC, was added to the US Food and Drug Administration (FDA) drug shortages list on April 14, 2017, due to an increased demand for the drug. The following are affected by the shortage:
- Phosphorus 15 mmol per 5 mL, Potassium 22 mEq per 5 mL, single dose vial (NDC 63323-086-05)
- Phosphorus 45 mmol per 15 mL, Potassium 66 mEq per 15 mL, single dose vial (NDC 63323-086-15)
- Phosphorus 150 mmol per 50 mL, Potassium 220 mEq per 50 mL, single dose vial (NDC 63323-086-50)
All of the presentations are backordered and are expected to become available in either May 2017 or June 2017.
Potassium phosphates injection, USP, 3 mM P/mL; 45 mM P/15 mL Single Dose Glass Fliptop Vial (NDC 00409-7295-01) from Hospira, Inc, is currently available after being on the FDA Drug Shortages list due to manufacturing delays.
The medication is used as a source of phosphate to prevent or treat hypophosphatemia in individuals with restricted or no oral intake. It is also indicated as an additive for preparing certain intravenous fluid formulas in some patients.
—Meredith Edwards White